Deerfield Management’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-5,780
Closed -$1.45M 126
2022
Q1
$1.45M Hold
5,780
0.03% 99
2021
Q4
$5.67M Sell
5,780
-3,506
-38% -$4.48M 0.12% 102
2021
Q3
$13.7M Buy
9,286
+4,378
+89% +$8.53M 0.27% 83
2021
Q2
$10.4M Buy
4,908
+800
+19% +$1.81M 0.18% 111
2021
Q1
$10.4M Sell
4,108
-1,500
-27% -$3.84M 0.22% 99
2020
Q4
$9.54M Buy
+5,608
New +$9.37M 0.19% 107

Other funds holding BCAB

Deerfield Management's BCAB Position: Q2 2022 in Review

Deerfield Management sold out of BioAtla (BCAB) in Q2 2022, closing a stake of 5,780 shares — an estimated $1.45M sold.

Deerfield Management first reported a position in BCAB in Q4 2020 and held it in 6 quarters. The position peaked at $13.7M in Q3 2021. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

  • Deerfield Management reported no remaining BioAtla position as of Q2 2022 after selling out during the quarter.
  • Deerfield Management sold 5,780 BioAtla shares in Q2 2022, an estimated $1.45M.
  • Deerfield Management first reported a position in BioAtla in Q4 2020 and held it in 6 quarters.
  • Deerfield Management's BioAtla position peaked at $13.7M in Q3 2021.
  • 76 funds tracked by Wall St. Rank held BioAtla as of Q2 2022.

Based on Deerfield Management's 13F filing for Q2 2022, filed 15 Aug 2022.